Awareness about Irritable Bowel Syndrome (IBS). A Survey Based Study

Safila Naveed*, Asra Hameed, Ammarah Urooj and Ramsha Mehak

Faculty of Pharmacy, Jinnah University for Women, Karachi –74600, Pakistan

*Corresponding author e-mail: safila117@yahoo.com

ABSTRACT

A bowel function disorder, irritable bowel syndrome (IBS) is very common problem that highly affects the quality of life of the patient. IBS may be diarrhoea predominant IBS (IBS-D), may be (IBS-C) constipation predominant IBS, and sometimes mixed bowel pattern (IBS-M) with both harden & loosen stools. Complications may include changes in bowel habits such as diarrhea or constipation, and pain in abdomen along with various symptoms including rectal urgency with diarrhea and abdominal bloating. Risk factors include age, anxiety, depression and adverse life Events. Prognostic techniques are colonoscopy and abdominal ultrasound. Different treatment strategies are used to treat various conditions experienced by individual patients. Drugs like antispasmodics, tricyclic antidepressants, 5-HT3 antagonists and probiotics are proved effective in this condition.

Objective: The survey aimed to find out Awareness about Irritable Bowel Syndrome (IBS) among the pharmacy graduates of 3rd to 5th professional Pharmacy.

Method: A Cross sectional and random method was used to collect data from university students. Data was analyzed and represented in the form of tables and graph.

Result: According to our survey, 74% students have basic information about IBS, 26% students have knowledge about the complications of IBS, 33% have knowledge about the risk factors of IBS, 7% have information about the prognosis of IBS and 53% students have knowledge about the treatment strategies of IBS.

Conclusion: The overall awareness is very low in pharmacy graduate.

Keywords: Bowel function, Irritable bowel syndrome, Diarrhoea, Constipation, Harden, Loosen stools.
INTRODUCTION

Irritable bowel syndrome

Irritable bowel syndrome (IBS) is a disorder of bowel with improper function. IBS is one of the common disorders and it affects the life of its patients deeply and makes them unable to function effectively in their societies. Studies have estimated the prevalence in the United States is somewhere between 15% and 20% of the whole population. IBS is a common disorder all around the world.1

Classification of IBS

IBS can be classified according to the predominant bowel habit. Around one third of IBS patients suffers from diarrhoea predominant IBS (IBS-D) and one third of IBS patients suffers from constipation predominant IBS (IBS-C), remaining one third of IBS patients suffers from a mixed bowel pattern (IBS-M) with both loosen & harden stools.2–4

Complications

Irritable bowel syndrome patient faces changes in bowel habits like abdominal pain, diarrhoea and constipation. Various symptoms are also associated with IBS including rectal urgency with diarrhea and abdominal bloating. A number of extra-intestinal symptoms are also associated with IBS, like pains & muscle aches, sexual dysfunction (libido lackness), fibromyalgia syndrome, fatigue, headaches, back pain, and many urinary symptoms including urinary urgency, hesitation in urine or a spasm feeling in the urinary bladder.1

Risk factors

Known risk factors in order of importance include the severity of the initial illness, bacterial toxigenicity,5 female sex, a range of adverse psychological factors like hypochondriasis,6 depression and anxiety,7 adverse life Events8 and Spiller9. Post infective IBS has been reported after shigella,10 salmonella,11,12 and campylobacter7 infections and does not appear specific to any particularorganism.13 Some other alarming features of irritable bowel syndrome are as under:21

- Age more than 50 years or elderly
- Nocturnal symptoms
- weight loss
- Recent antibiotic use
- Family history of colon cancer
- Male sex
- Anaemia
- Rectal bleeding

Prognosis

IBS is not associated with development of any serious disease.14,15 IBS is not linked to mortality. Patients may undergo certain surgical procedures like cholecystectomy & hysterectomy. Prognosis of IBS is depends on the available treatments. Patients suffering IBS should see their physician for health improve.16–19

The other key prognostic factor is chronic ongoing life stress which virtually precluded recovery in one study in which no patient with ongoing life stresses recovered over a 16 month follow up, compared with 41% without such stresses.20

Investigation for irritable bowel syndrome21

- Take a symptom history
- Assess psychosocial factors
- Physical examination
- Check for alarm symptoms
- Investigations
  - CBC
  - EMA (endomysial antibodies)
  - Lactose breath hydrogen test
  - Colonoscopy
  - Abdominal ultrasound
Treatment of IBS

Many people in our society daily experience IBS symptoms just because of their IBS history. There was no effective treatment of IBS. IBS patients should go to their physician for their recommendations for latest treatment options. Physician should counsel their patients that IBS is a chronic illness. Only symptomatic treatments are provided so the overall outlook is actually quite good.¹

IBS is a heterogeneous condition with a wide range for treatment, each of which benefits a small proportion of IBS patients. Treatment of associated depression & anxiety often improves bowel and other symptoms. Randomized trials showed benefit as follows: cognitive behavioral therapy and psychodynamic interpersonal therapy improve coping; hypnotherapy benefits global symptoms. Antispasmodics and tricyclic antidepressants can improve pain of IBS patients. Ispaghula can improve pain and bowel habit of IBS patients. 5-HT3 antagonists improve global symptoms, diarrhoea and pain of IBS patients. It can cause unexplained colitis. 5-HT4 agonists improve global symptoms, bloating and constipation of IBS patients. Selective serotonin reuptake inhibitors improve global symptoms in IBS patients.²¹ (See table 6.)

METHODOLOGY

This is a survey based study on the awareness of irritable bowel syndrome (IBS). A cross-sectional and random method was used to collect data from Department of Pharmacy, Jinnah University for Women, about the awareness on irritable bowel syndrome (IBS) in the month of Sep-Oct, 2014. A specially designed questionnaire was used for data collection. Data of 100 female students (n=100) was collected from 3rd, 4th and 5th professional year students and analyzed. Different questions were asked form the subjects to collect the data and to conclude the awareness rate in university students about IBS. Questions were asked on the basic knowledge or introduction of IBS, its complications, its risk factors, its prognosis and the treatment strategies of IBS (figure 1).

Data analysis

We have statistically analyzed our data and used tables and graph for the representation of our data collected.

RESULT

After our survey on the awareness of IBS, at JUW, Karachi, we found that only 29.4% of the pharmacy undergraduate Students belong to 3rd,4th and 5th professional pharmacy have awareness while other 70.6% of the pharmacy undergraduate Students belong to 3rd, 4th and 5th professional pharmacy have no awareness about irritable bowel syndrome (IBS).

DISCUSSION

A bowel function disorder, irritable bowel syndrome (IBS) is very common problem that highly affects the quality of life of the patient. Irritable bowel syndrome IBS may be diarrhoea predominant (IBS-D) and may be constipation predominant (IBS-C) and may be mixed pattern (IBS-M) with both harden & loosen stools. Our survey aims to find its awareness in 3rd, 4th and 5th professional pharmacy students at Jinnah University for women, Karachi. We had asked different questions about IBS during our survey.

In our survey about the awareness of irritable bowel syndrome (IBS) the first question was asked about IBS that “What is irritable bowel syndrome (IBS)?” to 100 students belong to 3rd, 4th and 5th professional pharmacy. 74 out of 100 pharmacy students had knowledge about IBS. While other 26 students of 3rd, 4th and 5th professional pharmacy had no basic
knowledge about irritable bowel syndrome (IBS). (Table 1)

In our survey about the awareness of irritable bowel syndrome (IBS) the second question was asked about the complications of IBS that “What are the complications of irritable bowel syndrome (IBS)?” to 100 students belong to 3rd, 4th and 5th professional pharmacy. 26 out of 100 pharmacy students had knowledge about the complications of IBS. While other 74 students of 3rd, 4th and 5th professional pharmacy had no knowledge about the complications of irritable bowel syndrome (IBS). (Table 2)

In our survey about the awareness of irritable bowel syndrome (IBS) the third question was asked about the risk factors of IBS that “What are the risk factors of irritable bowel syndrome (IBS)?” to 100 students belong to 3rd, 4th and 5th professional pharmacy. 33 out of 100 pharmacy students had knowledge about the risk factors of IBS. While other 67 students of 3rd, 4th and 5th professional pharmacy had no knowledge about the risk factors of irritable bowel syndrome (IBS). (Table 3)

In our survey about the awareness of irritable bowel syndrome (IBS) the fourth question was asked about the risk factors of IBS that “What are the prognosis of irritable bowel syndrome (IBS)?” to 100 students belong to 3rd, 4th and 5th professional pharmacy. 7 out of 100 pharmacy students had knowledge about the prognosis of IBS. While other 93 students of 3rd, 4th and 5th professional pharmacy had no knowledge about the prognosis of irritable bowel syndrome (IBS). (Table 4)

In our survey about the awareness of irritable bowel syndrome (IBS) the last question was asked about the treatment of IBS that “What are the treatment of irritable bowel syndrome (IBS)?” to 100 students belong to 3rd, 4th and 5th professional pharmacy. 7 out of 100 pharmacy students had knowledge about the treatment strategies of IBS. While other 93 students of 3rd, 4th and 5th professional pharmacy had no knowledge about the treatment strategies of irritable bowel syndrome (IBS). (Table 5) we had done these types of survey based studies which is very useful for health care professionals.22-40.

CONCLUSION

After our survey on the awareness of IBS at JUW, Karachi, we find the overall awareness rate of IBS is very low among the students of pharmacy belong to 3rd, 4th and 5th profession. There was only 29.4% female students of pharmacy who aware about this inflammatory condition.

REFERENCES

24. Safila Naveed*, Naila Rehman, Shumaila Rehman, Sana Malick, Shahnaz Yousuf, Sarah Marium, Sidrah Khan, Rabiya Ali, Aisha Akhter] (2014) Knowledge and Attitude about Crimean Congo Hemorrhagic Fever (CCHF) Amongst Local Residents Of Karachi, Pakistan Accepted J App Pharm Vol. 6; Issue 2: 166-170; IF 0.4 http://nebula.wsimg.com/527c0cb84a8325329f3b 0f76ef6fa4a?AccessKeyId=4323AF8BFBC 2D34AB0BD&disposition=0&alloworigin= 1.


35. Safila Naveed,Ghulam Sarwar, Raazia Hassan , Sehrish Khan , Saima Afzal , Seeme Naz Rabia Gulam Nabi and Sara Yaseen, Irrational use of cephalosporin and quinolones in public and private sectors hospitals of Karachi J App Pharm Vol. 6; Issue 3: 252 -260; (ISSN 19204159); www.japharmacy.ca IF 0.4 (http://nebula. wsiimg.com/8bff5601ea81ccfedf0164a8014 917?AccessKeyId=4323AF8FBBC2D34AB0BD&disposition=0&alloworigin=1).


Table 1. Basic knowledge about irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
<th>Percent</th>
<th>Valid percent</th>
<th>Cumulative percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid No</td>
<td>26</td>
<td>26.0</td>
<td>26.0</td>
<td>26.0</td>
</tr>
<tr>
<td>Yes</td>
<td>74</td>
<td>74.0</td>
<td>74.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Complications of irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
<th>Percent</th>
<th>Valid percent</th>
<th>Cumulative percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid No</td>
<td>74</td>
<td>74.0</td>
<td>74.0</td>
<td>74.0</td>
</tr>
<tr>
<td>Yes</td>
<td>26</td>
<td>26.0</td>
<td>26.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Risk factors of irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
<th>Percent</th>
<th>Valid percent</th>
<th>Cumulative percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid No</td>
<td>67</td>
<td>67.0</td>
<td>67.0</td>
<td>67.0</td>
</tr>
<tr>
<td>Yes</td>
<td>33</td>
<td>33.0</td>
<td>33.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Prognosis of irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
<th>Percent</th>
<th>Valid percent</th>
<th>Cumulative percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valid No</td>
<td>93</td>
<td>93.0</td>
<td>93.0</td>
<td>93.0</td>
</tr>
<tr>
<td>Yes</td>
<td>7</td>
<td>7.0</td>
<td>7.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>
Table 5. Treatment strategies of irritable bowel syndrome (IBS)

<table>
<thead>
<tr>
<th></th>
<th>Frequency</th>
<th>Percent</th>
<th>Valid percent</th>
<th>Cumulative percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>93</td>
<td>93.0</td>
<td>93.0</td>
<td>93.0</td>
</tr>
<tr>
<td>Yes</td>
<td>7</td>
<td>7.0</td>
<td>7.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Total</td>
<td>100</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

Table 6. Suggested sequence of pharmacological treatment for irritable bowel syndrome\textsuperscript{21}

<table>
<thead>
<tr>
<th>Predominant symptom</th>
<th>First line</th>
<th>Second line</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>Antispasmodic agents</td>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Psychological treatments</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Loperamide</td>
<td>5-HT3 antagonist*</td>
</tr>
<tr>
<td>Constipation</td>
<td>Ispaghula</td>
<td>5-HT4 agonist*</td>
</tr>
<tr>
<td>Bloating with distension</td>
<td>Dietary manipulation</td>
<td>Probiotics</td>
</tr>
<tr>
<td></td>
<td>Polyethylene glycols</td>
<td>5-HT4 agonist*</td>
</tr>
<tr>
<td>Bloating without distension</td>
<td>Antispasmodic agents</td>
<td>Probiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tricyclics</td>
</tr>
</tbody>
</table>

*No representative of this class of drugs is currently licensed for IBS but there are other related drugs in development.

Figure 1. Awareness about IBS